We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ICON Central Laboratories Doubles Biospecimen Storage Capacity

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

ICON plc has announced that it has expanded the biorepository capacity in its Central Laboratory located in Farmingdale, New York.

The expansion doubles ICON’s sample storage capacity globally and supports the long term sample storage needs of clinical trials.

“We’re investing in this expansion to meet our sponsor’s biorepository needs and because we believe that long-term preservation of samples is essential for the future of drug development, in particular for personalized medicine strategies that foresee an ever-increasing need for downstream analysis,” commented Tom O’Leary, President, ICON Central Laboratories.

Tom O’Leary continued, “The co-location of our biorepository services with our central labs in North America, Europe, Singapore and India is critical, as it allows for future analysis while minimizing the risks and costs associated with transporting samples.”

ICON’s global biorepository facilities store a wide-range of specimens, including plasma, serum, whole blood, RNA, DNA, peripheral blood mononuclear cell (PBMC), urine and tissue at frozen storage conditions of -20°C, -70°C, -80°C, and -150°C liquid nitrogen.

This latest expansion provides additional capacity to ICON’s existing end-to-end biospecimen management solution, which ensures sample integrity and full chain of custody across the entire lifecycle from collection and processing to final disposal.